Design and Evaluation of Eb₄Mab-7-mG_2a: A Dual-Action Anti-EphB4 Monoclonal Antibody for Targeted Breast Cancer Therapy.

ABSTRACT: Breast cancer remains a leading cause of cancer mortality worldwide, underscoring the urgent need for novel and effective therapeutic strategies. Eph receptor tyrosine kinases, particularly EphB4, exhibit diverse roles in cancer biology, acting as either tumor promoters or suppressors depending on the cellular environment and ligand engagement. EphB4 is frequently overexpressed in breast cancer and contributes to dysregulated signaling and tumor progression through the abnormal interaction with its ligand Ephrin-B2. We herein developed an improved anti-EphB4 monoclonal antibody, Eb₄Mab-7-mG_2a, which can be characterized as a subclass-switched IgG_2a variant designed to enhance immune effector function, specifically antibody-dependent cellular cytotoxicity (A

SUBMITTER: Ohishi T 

PROVIDER: S-EPMC12666464 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature